Ryan Scott

Dr. Andrew Evens explained how treatment and trials for lymphoma differ in adolescent and young adult patients compared with children or older adults. The treatment approach to adolescent and young adult (AYA) patients with lymphoma (a kind of blood cancer) […]

The FDA’s advisory panel voted against expanded use of Talzenna/Xtandi for prostate cancer and UGN-102 for recurrent bladder cancer, citing safety and efficacy concerns. The United States Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has casted their

JAK inhibitors ease myelofibrosis symptoms but not the disease itself; newer treatments like Ojjaara aim to improve anemia and offer better quality of life. Myelofibrosis is a Philadelphia-negative myeloproliferative neoplasms (MPN) and can occur as de novo disease. Myelofibrosis creates

An FDA panel backed Darzalex Faspro for smoldering myeloma but opposed Columvi plus chemo for relapsed/refractory lymphoma due to trial limitations. The United States Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has casted their votes on the

Dr. Ranjit S. Bindra discusses recent advancements for the treatment of patients with primary brain tumors during Brain Cancer Awareness Month. Recent advancements like proton therapy, radiosurgery and image-guided precision, have elicited more personalized care and better outcomes for patients

Patients without TP53 mutations or liver metastases saw longer progression-free survival with samuraciclib combos after CDK4/6 inhibitor therapy. Results from two phase 2 trials support treatment with the novel, first-in-class inhibitor samuraciclib for the treatment of patients with hormone receptor

Dr. Daniel Petrylak highlights the importance of early detection and evolving treatments for bladder cancer during Bladder Cancer Awareness Month. The month of May serves as Bladder Cancer Awareness Month and aims to promote both early detection and support for

The FDA approved the Ventana MET RxDx assay to guide Emrelis use in patients with non-squamous non–small cell lung cancer and high MET protein expression. The Ventana MET (SP44) RxDx assay has received approval from the United States Food and

CX-2051 led to tumor responses and disease control in patients with late-line colorectal cancer, with a favorable safety profile. Treatment with the epithelial cell adhesion molecule (EpCAM) PROBODY antibody-drug conjugate CX-2051 demonstrated responses in patients with advanced, late-line colorectal cancer,

For adult patients with previously treated, advanced NSCLC with high c-Met protein overexpression, the U.S. FDA has approved treatment with Emrelis. The United States Food and Drug Administration (FDA) has approved treatment with Emrelis for adult patients with previously treated,